CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes

Rhea-AI Filing Summary

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity grants, vesting, and a small share sale tied to taxes. He received a stock option for 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting on April 20, 2026. He was also granted 25,000 Restricted Stock Units (RSUs) that will vest in four annual installments of 6,250 shares each from March 20, 2027 through March 20, 2030.

On March 20, 2026, 6,250 RSUs from a prior 2024 grant vested and were converted into 6,250 Common Shares. On March 23, 2026, 3,182 Common Shares were sold at $46.78 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, Kasinger directly held 94,308 Common Shares, which remain subject to a lock-up agreement related to the company’s offering of convertible senior notes due 2031.

Insider Trade Summary

Net Seller: 3,182 shares ($148,854)

Net Sell 5 txns

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Sold 3,182 shs ($149K)

Type	Security	Shares	Price	Value
Sale	Common Shares	3,182	$46.78	$149K
Grant/Award	Stock Option (Right to Buy)	38,499	$0.00	--
Grant/Award	Restricted Stock Units	25,000	$0.00	--
Exercise	Restricted Stock Units	6,250	$0.00	--
Exercise	Common Shares	6,250	$0.00	--

Holdings After Transaction: Common Shares — 94,308 shares (Direct); Stock Option (Right to Buy) — 38,499 shares (Direct); Restricted Stock Units — 25,000 shares (Direct)

Footnotes (1)

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/20/2026		M(1)		6,250	A	(2)	97,490	D
Common Shares	03/23/2026		S		3,182(3)	D	$46.78	94,308	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.24	03/20/2026		A(1)		38,499		(4)	03/20/2036	Common Shares	38,499	$0.00	38,499	D
Restricted Stock Units	(2)	03/20/2026		A(1)		25,000		(5)	(5)	Common Shares	25,000	$0.00	25,000	D
Restricted Stock Units	(2)	03/20/2026		M(1)			6,250	(6)	(6)	Common Shares	6,250	(2)	12,000	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

5. This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

6. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did CRISPR Therapeutics (CRSP) grant to James R. Kasinger?

James R. Kasinger received two major equity awards. He was granted a stock option for 38,499 Common Shares at a $46.24 exercise price and 25,000 Restricted Stock Units, vesting in four equal annual installments from March 20, 2027 through March 20, 2030.

How many CRISPR Therapeutics (CRSP) shares did James R. Kasinger sell in this Form 4?

Kasinger sold 3,182 Common Shares at $46.78 per share. A footnote explains this sale was required to cover tax withholding obligations from RSU vesting under the company’s RSU Settlement Policy and was not a discretionary trade.

What happened to James R. Kasinger’s Restricted Stock Units at CRISPR Therapeutics (CRSP)?

Some RSUs vested and new RSUs were granted. On March 20, 2026, 6,250 RSUs from a 2024 grant vested and converted into 6,250 Common Shares, while a new 25,000-unit RSU award with four annual vesting tranches was granted the same day.

How many CRISPR Therapeutics (CRSP) Common Shares does James R. Kasinger hold after these transactions?

After the reported transactions, Kasinger directly held 94,308 Common Shares. The filing notes these shares remain subject to a lock-up agreement connected to the company’s offering of convertible senior notes due 2031.

Are James R. Kasinger’s CRISPR Therapeutics (CRSP) share sales considered discretionary trades?

The filing states the reported sale was not discretionary. A footnote explains the 3,182-share sale was mandated by the company’s RSU Settlement Policy solely to fund tax withholding obligations on vested RSUs, rather than reflecting an elective market decision.

What are the key vesting terms of James R. Kasinger’s new CRISPR Therapeutics (CRSP) stock option?

The new option covers 38,499 Common Shares at $46.24. According to the filing, 100% of the shares vest in 48 equal monthly installments, with the first vesting date on April 20, 2026, creating a four-year monthly vesting schedule.